Leerink Partners Initiates Coverage on Kailera Therapeutics (NASDAQ:KLRA)

Research analysts at Leerink Partners initiated coverage on shares of Kailera Therapeutics (NASDAQ:KLRA) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $36.00 price target on the stock. Leerink Partners’ price target points to a potential upside of 70.54% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. Jefferies Financial Group began coverage on shares of Kailera Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $48.00 price target for the company. TD Cowen assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $57.00 price target for the company. William Blair began coverage on Kailera Therapeutics in a research report on Tuesday. They set an “outperform” rating for the company. Evercore initiated coverage on Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating for the company. Finally, Wall Street Zen upgraded shares of Kailera Therapeutics to a “hold” rating in a research note on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $42.75.

Kailera Therapeutics Trading Down 5.3%

NASDAQ KLRA opened at $21.11 on Tuesday. Kailera Therapeutics has a 1 year low of $20.86 and a 1 year high of $28.23.

Insider Buying and Selling at Kailera Therapeutics

In other news, Director Andrew T. Kaplan purchased 8,398,438 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the acquisition, the director directly owned 26,255,581 shares of the company’s stock, valued at approximately $420,089,296. The trade was a 47.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Rtw Investments, Lp purchased 500,000 shares of the stock in a transaction dated Monday, April 20th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $8,000,000.00. Following the completion of the transaction, the insider owned 10,776,820 shares of the company’s stock, valued at $172,429,120. The trade was a 4.87% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 10,460,938 shares of company stock worth $167,375,008 over the last ninety days.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.